Peter Clark to Neoplasm Staging
This is a "connection" page, showing publications Peter Clark has written about Neoplasm Staging.
Connection Strength
1.968
-
Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Clark PE. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
Score: 0.308
-
Balci M, Glaser ZA, Chang SS, Herrell SD, Barocas DA, Keegan KA, Moses KA, Resnick MJ, Smith JA, Penson DF, Scarpato K, Clark PE. Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. J Cancer Res Ther. 2021 Apr-Jun; 17(2):420-425.
Score: 0.178
-
Glaser ZA, Love HD, Guo S, Gellert L, Chang SS, Herrell SD, Barocas DA, Penson DF, Cookson MS, Clark PE. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
Score: 0.133
-
Clark PE. T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. Pro. Oncology (Williston Park). 2013 Sep; 27(9):872, 921.
Score: 0.106
-
Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615.
Score: 0.103
-
Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75.
Score: 0.102
-
Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011 Jun; 59(6):923-8.
Score: 0.088
-
Clark PE. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1343-4.
Score: 0.077
-
Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
Score: 0.076
-
Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Duke Herrell S, Smith JA, Clark PE. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
Score: 0.076
-
Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol. 2007 Sep; 17(5):331-6.
Score: 0.070
-
Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005 Feb 01; 103(3):546-52.
Score: 0.058
-
Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004 Oct; 172(4 Pt 1):1342-7.
Score: 0.057
-
Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61.
Score: 0.053
-
Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan; 37(1):3-13.
Score: 0.037
-
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267.
Score: 0.035
-
Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017 Jan 03; 8(1):722-741.
Score: 0.033
-
Gregg JR, McCormick B, Wang L, Cohen P, Sun D, Penson DF, Smith JA, Clark PE, Cookson MS, Barocas DA, Resnick MJ, Moses KA, Chang SS. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
Score: 0.032
-
Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA, Barocas DA. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
Score: 0.028
-
Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA, Chang SS. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014 Jun; 113(6):894-9.
Score: 0.027
-
Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Current concepts in penile cancer. J Natl Compr Canc Netw. 2013 May 01; 11(5):617-24.
Score: 0.026
-
Ritch CR, Clark PE, Morgan TM. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how? Urol Clin North Am. 2013 May; 40(2):295-304.
Score: 0.025
-
DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
Score: 0.024
-
Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2013 Aug; 31(6):812-26.
Score: 0.023
-
DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013 Aug; 31(6):802-11.
Score: 0.023
-
Anderson CB, Clark PE, Morgan TM, Stratton KL, Herrell SD, Davis R, Cookson MS, Smith JA, Chang SS. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
Score: 0.022
-
Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA, Chang SS. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
Score: 0.021
-
Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
Score: 0.020
-
Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
Score: 0.019
-
Chan RC, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA, Cookson MS. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
Score: 0.018
-
Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
Score: 0.018
-
Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol. 2007 Apr; 30(2):199-204.
Score: 0.017
-
Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5.
Score: 0.014
-
Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003 May; 15(3):227-33.
Score: 0.013
-
Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol. 1995 Mar; 153(3 Pt 2):981-5.
Score: 0.007